216 related articles for article (PubMed ID: 22040825)
1. [Frontiers in vitamin D; basic research and clinical application. Inhibitory effects of eldecalcitol, an active vitamin D derivative, on bone resorption in vivo].
Harada S; Mizoguchi T; Takahashi N
Clin Calcium; 2011 Nov; 21(11):91-8. PubMed ID: 22040825
[TBL] [Abstract][Full Text] [Related]
2. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone.
Harada S; Mizoguchi T; Kobayashi Y; Nakamichi Y; Takeda S; Sakai S; Takahashi F; Saito H; Yasuda H; Udagawa N; Suda T; Takahashi N
J Bone Miner Res; 2012 Feb; 27(2):461-73. PubMed ID: 22052469
[TBL] [Abstract][Full Text] [Related]
3. [Frontiers in vitamin D; basic research and clinical application. Eldecalcitol: the effect on bones and calcium metabolism].
Endo I; Matsumoto T
Clin Calcium; 2011 Nov; 21(11):103-10. PubMed ID: 22040826
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of inhibitory action of eldecalcitol, an active vitamin D analog, on bone resorption in vivo.
Takahashi N
J Steroid Biochem Mol Biol; 2013 Jul; 136():171-4. PubMed ID: 23220095
[TBL] [Abstract][Full Text] [Related]
5. [Current Topics on Vitamin D. Treatment of osteoporosis with eldecalcitol: Its therapeutic efficacy and adverse effect on renal function].
Takeuchi Y
Clin Calcium; 2015 Mar; 25(3):425-32. PubMed ID: 25716816
[TBL] [Abstract][Full Text] [Related]
6. Eldecalcitol and calcitriol stimulates 'bone minimodeling,' focal bone formation without prior bone resorption, in rat trabecular bone.
Saito H; Takeda S; Amizuka N
J Steroid Biochem Mol Biol; 2013 Jul; 136():178-82. PubMed ID: 23069645
[TBL] [Abstract][Full Text] [Related]
7. Eldecalcitol: newly developed active vitamin D(3) analog for the treatment of osteoporosis.
Hagino H
Expert Opin Pharmacother; 2013 Apr; 14(6):817-25. PubMed ID: 23477453
[TBL] [Abstract][Full Text] [Related]
8. [Frontiers in vitamin D; basic research and clinical application. A review on histological findings in bones administered with eldecalcitol].
Hongo H; Sasaki M; Hasegawa T; Amizuka N
Clin Calcium; 2011 Nov; 21(11):63-70. PubMed ID: 22040822
[TBL] [Abstract][Full Text] [Related]
9. Eldecalcitol for the treatment of osteoporosis.
Matsumoto T; Endo I
Drugs Today (Barc); 2012 Mar; 48(3):189-96. PubMed ID: 22462038
[TBL] [Abstract][Full Text] [Related]
10. [Frontiers in vitamin D; Basic research and clinical application. The effects of eldecalcitol on bone mineral density and fracture prevention--Post hoc analysis].
Hagino H
Clin Calcium; 2011 Nov; 21(11):111-8. PubMed ID: 22040827
[TBL] [Abstract][Full Text] [Related]
11. Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation.
Jiang Y; Tang H; Ma X; Cheng Q; Lin H; Jin X; Zhang Z; Yu W; He S; Kobayashi T; Uehara S; Matsumoto T; Xia W
J Bone Miner Metab; 2019 Nov; 37(6):1036-1047. PubMed ID: 31087185
[TBL] [Abstract][Full Text] [Related]
12. Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats.
Sakai S; Takeda S; Sugimoto M; Shimizu M; Shimonaka Y; Yogo K; Hashimoto J; Bauss F; Endo K
Bone; 2015 Dec; 81():449-458. PubMed ID: 26281770
[TBL] [Abstract][Full Text] [Related]
13. [Frontiers in vitamin D; Basic research and clinical application. Effect of eldecalcitol on bone structure].
Ito M
Clin Calcium; 2011 Nov; 21(11):119-25. PubMed ID: 22040828
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional and potent roles of the 3-hydroxypropoxy group provide eldecalcitol's benefit in osteoporosis treatment.
Ono Y
J Steroid Biochem Mol Biol; 2014 Jan; 139():88-97. PubMed ID: 24139874
[TBL] [Abstract][Full Text] [Related]
15. Histological Effects of the Combined Administration of Eldecalcitol and a Parathyroid Hormone in the Metaphyseal Trabeculae of Ovariectomized Rats.
Hasegawa T; Yamamoto T; Sakai S; Miyamoto Y; Hongo H; Qiu Z; Abe M; Takeda S; Oda K; de Freitas PHL; Li M; Endo K; Amizuka N
J Histochem Cytochem; 2019 Mar; 67(3):169-184. PubMed ID: 30311820
[TBL] [Abstract][Full Text] [Related]
16. [Recent progress and problem of treatment with active vitamin D].
Fukumoto S
Clin Calcium; 2014 Jan; 24(1):53-8. PubMed ID: 24369280
[TBL] [Abstract][Full Text] [Related]
17. Eldecalcitol: a review of its use in the treatment of osteoporosis.
Sanford M; McCormack PL
Drugs; 2011 Sep; 71(13):1755-70. PubMed ID: 21902297
[TBL] [Abstract][Full Text] [Related]
18. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
[TBL] [Abstract][Full Text] [Related]
19. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
Iba K; Sonoda T; Takada J; Dohke T; Yamashita T
J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
[TBL] [Abstract][Full Text] [Related]
20. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
Nakatoh S
J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
